GroPep offloads IP to concentrate on protein pharma
01 March, 2002 by Tanya HollisSouth Australian drug discovery company GroPep (ASX:GRO) has begun selling off sections of its newly acquired intellectual property treasure chest.
Cash injection boosts Amrad R&D program
01 March, 2002 by Tanya HollisDrug developer Amrad Corporation has raised $15.5 million in capital to help progress its clinical trials program.
R&D spend dominates BresaGen half-year
28 February, 2002 by Daniella GoldbergAustralian biotechnology company BresaGen's half-year results to December 2001 show an increase in revenue by 15 per cent, to $3,661,000, over the same period a year ago.
AgVic's genetic hens join the elites
28 February, 2002 by Tanya HollisAgriculture Victoria's 40-year bantamised hen project has entered the commercialisation phase, beginning a joint research deal with an elite international breeder.
Axon releases new drug discovery tool
28 February, 2002 by Tanya HollisA screening instrument that enables drug company technicians to run parallel tests has been released by Melbourne-based company Axon Instruments (ASX: AXN).
Shellfish gene helps Brisbane biotech
27 February, 2002 by Pete YoungBrisbane biotech business Xenome Ltd is moving closer to human trials with a pain-killing molecule derived from the venom of a marine shellfish.
MicroMedical's human heart trials imminent
26 February, 2002 by Tanya HollisAustralia's first artificial hearts are to be implanted in human patients within weeks, according to the developer.
New IMB research targets cystic fybrosis
25 February, 2002 by Pete YoungQueensland bioresearchers have discovered a promising method for treating a common bacterial infection afflicting cystic fibrosis patients.
No GM wheat here: Monsanto
22 February, 2002 by Melissa TrudingerThe Australian branch of agricultural biotechnology giant Monsanto today refuted reports that its herbicide resistant genetically modified wheat seed was taking longer than expected to gain approval in the US.
Heavyweight board a coup for start-up Farmacule
22 February, 2002 by Pete YoungQueensland molecular farming start-up Farmacule Bioindustries has scored a mini-coup by appointing ex-Dow Chemical heavyweight Dr Paul Zorner to its board.
Peptech stands by directors' remuneration
21 February, 2002 by Daniella GoldbergThe Australian Shareholders Association (ASA) has clashed with Sydney biotech company Peptech over the company's remuneration of non-executive board members.
Xenotransplants: not quite around the corner
21 February, 2002 by Daniella GoldbergPig hearts, kidneys and livers could be available for transplant into humans within five to seven years, according to the latest reports from the American Association for the Advancement of Science meeting currently underway in Boston.
Acyte Biotech capitalises on tiny microbes
21 February, 2002 by Daniella GoldbergTwo major multinational pharmaceutical companies and two ASX-listed biotechs are vying for the a new biopharmaceutical platform technology developed by Acyte Biotech, a spin-off company from the University of New South Wales.
Hong Kong destined for best supporting role in biotech
21 February, 2002 by Chee Sing ChanAnalysts and industry experts are widely predicting biotechnology and life sciences to be strong growth areas this year, but in comparison to other Asian markets, Hong Kong seems off the pace.
CSL looks to the US after solid half-year result
21 February, 2002 by Tanya HollisBlood products and vaccine manufacturer CSL has announced it more than doubled its interim profit to $57.5 million on the back of its acquisition of Swiss plasma supplier ZLB last year.
